|
liver transplantation |
23 |
|
hepatocellular carcinoma |
18 |
|
medical sciences |
13 |
|
gastroenterology medical sciences |
12 |
|
surgery |
12 |
|
inflammation |
11 |
|
cell proliferation |
10 |
|
tumor recurrence |
10 |
|
apoptosis |
9 |
|
cell line, tumor |
9 |
|
immunosuppressive agents - therapeutic use |
9 |
|
invasiveness |
9 |
|
ischemia-reperfusion injury |
9 |
|
sphingosine - analogs & derivatives |
9 |
|
down-regulation |
8 |
|
focal adhesion kinase 2 - metabolism |
8 |
|
hepatectomy |
8 |
|
humans |
8 |
|
marginal graft |
8 |
|
metastasis |
8 |
|
mitochondrion |
8 |
|
propylene glycols - pharmacology |
8 |
|
recurrence |
8 |
|
steatosis |
8 |
|
survival |
8 |
|
adolescent |
7 |
|
adult |
7 |
|
animals |
7 |
|
anti-steatosis |
7 |
|
carcinoma, hepatocellular - blood supply - drug therapy - pathology |
7 |
|
carcinoma, hepatocellular - enzymology - genetics |
7 |
|
carcinoma, hepatocellular - genetics - metabolism - pathology - virology |
7 |
|
carcinoma, hepatocellular - metabolism - pathology |
7 |
|
cell survival signaling |
7 |
|
chemokine cxcl10 - metabolism |
7 |
|
disease-free survival |
7 |
|
fatty liver - pathology - surgery |
7 |
|
fty720 |
7 |
|
glycogen synthase kinase 3 - metabolism |
7 |
|
graft rejection - blood - drug therapy - pathology |
7 |
|
graft survival - drug effects |
7 |
|
hepatic microcirculation |
7 |
|
immunosuppressive agents - pharmacology |
7 |
|
liver graft injury |
7 |
|
liver neoplasms - enzymology - genetics |
7 |
|
liver neoplasms - genetics - metabolism - pathology - virology |
7 |
|
liver neoplasms - metabolism - pathology |
7 |
|
liver neoplasms, experimental - blood supply - drug therapy - pathology |
7 |
|
macrophage |
7 |
|
matrix metalloproteinase 9 - metabolism |
7 |
|
neovascularization, pathologic - drug therapy |
7 |
|
proline-rich tyrosine kinase2 (pyk2) |
7 |
|
propylene glycols - therapeutic use |
7 |
|
proto-oncogene proteins c-akt |
7 |
|
signal transduction |
7 |
|
stat5 transcription factor - biosynthesis - genetics - metabolism |
7 |
|
tumor cells, cultured |
7 |
|
akt signaling pathway |
6 |
|
angiogenesis |
6 |
|
angiopoietin-like 4 |
6 |
|
antigens, cd34 - metabolism |
6 |
|
apoptosis - drug effects |
6 |
|
bile |
6 |
|
biliary |
6 |
|
blotting, western |
6 |
|
cancer |
6 |
|
carcinoma |
6 |
|
carcinoma, hepatocellular - drug therapy - metabolism - secondary |
6 |
|
carcinoma, hepatocellular - genetics - metabolism - pathology |
6 |
|
carcinoma, hepatocellular - genetics - prevention and control - secondary |
6 |
|
cd274 |
6 |
|
cdna microarray |
6 |
|
cell adhesion molecules |
6 |
|
cell cycle proteins - metabolism |
6 |
|
cell movement |
6 |
|
chemokines |
6 |
|
cholangiocarcinoma |
6 |
|
cholangitis |
6 |
|
cyclin d1 - metabolism |
6 |
|
cyclin-dependent kinase inhibitor p27 |
6 |
|
disease models, animal |
6 |
|
enzyme inhibitors - pharmacology |
6 |
|
epithelial-mesenchymal transition |
6 |
|
extracellular signal-regulated map kinases - metabolism |
6 |
|
focal adhesion kinase |
6 |
|
g1 phase - drug effects |
6 |
|
gene expression profiling |
6 |
|
gpx3 |
6 |
|
graft injury |
6 |
|
graft survival |
6 |
|
hcc |
6 |
|
hepatectomy - adverse effects |
6 |
|
hepatocellular carcinoma (hcc) |
6 |
|
hfe |
6 |
|
hipsc-mscs |
6 |
|
homeodomain proteins - antagonists and inhibitors - genetics - metabolism |
6 |
|
homeodomain proteins - genetics - metabolism |
6 |
|
homeoprotein six1 |
6 |
|
hpyv6 |
6 |
|
interference |
6 |
|
intragraft gene expression profiles |
6 |
|
kidney neoplasms - genetics - prevention and control - secondary |
6 |
|
lipocalins |
6 |
|
liver - blood supply - metabolism - pathology - surgery |
6 |
|
liver neoplasms - genetics - metabolism - pathology |
6 |
|
liver neoplasms, experimental - drug therapy - metabolism - pathology |
6 |
|
liver neoplasms, experimental - genetics - pathology - prevention and control |
6 |
|
liver neoplasms, experimental - metabolism - pathology - surgery |
6 |
|
lung neoplasms - etiology - metabolism - secondary |
6 |
|
m2 macrophages |
6 |
|
malignancy |
6 |
|
map kinase signaling system - drug effects |
6 |
|
mice |
6 |
|
mice, nude |
6 |
|
microcirculation |
6 |
|
mitogen-activated protein kinase 1 - antagonists & inhibitors - metabolism |
6 |
|
mitogen-activated protein kinase 3 - antagonists & inhibitors - metabolism |
6 |
|
neoplasm metastasis |
6 |
|
neoplasm recurrence, local - etiology - metabolism - pathology |
6 |
|
neovascularization, pathologic - prevention & control |
6 |
|
pathologic tumour-node-metastasis (ptnm) stage |
6 |
|
phosphatidylinositol 3-kinases - antagonists & inhibitors - metabolism |
6 |
|
phosphatidylinositol 3-kinases - metabolism |
6 |
|
phosphorylation - drug effects |
6 |
|
polyomavirus |
6 |
|
prognosis |
6 |
|
prognostic predictor |
6 |
|
protein-serine-threonine kinases - metabolism |
6 |
|
proto-oncogene proteins - metabolism |
6 |
|
rac gtp-binding proteins - chemistry - metabolism |
6 |
|
rac gtp-binding proteins - metabolism |
6 |
|
rna, small interfering - pharmacology |
6 |
|
short hairpin rna (shrna) |
6 |
|
six1 |
6 |
|
small-for-size fatty liver |
6 |
|
therapeutic |
6 |
|
tumor suppressor gene |
6 |
|
tumor suppressor protein p53 - metabolism |
6 |
|
tumor suppressor proteins - metabolism |
6 |
|
vascular endothelial growth factor a - metabolism |
6 |
|
venous infiltration |
6 |
|
wound healing |
6 |
|
acute-phase reaction - metabolism - pathology |
5 |
|
adenosine - chemistry |
5 |
|
akt |
5 |
|
akt survival pathway |
5 |
|
alanine transaminase - blood |
5 |
|
allergology and immunology |
5 |
|
allopurinol - chemistry |
5 |
|
animal models |
5 |
|
apolipoprotein c-iii |
5 |
|
apolipoproteins c - metabolism |
5 |
|
aspartate aminotransferases - blood |
5 |
|
biopsy |
5 |
|
cancer cell culture |
5 |
|
carcinoma, hepatocellular - enzymology - pathology |
5 |
|
carcinoma, hepatocellular - enzymology - pathology - ultrastructure |
5 |
|
ccaat-enhancer-binding proteins - physiology |
5 |
|
cell fusion |
5 |
|
cell movement - physiology |
5 |
|
chemicals and cas registry numbers |
5 |
|
chemokine cxcl2 |
5 |
|
chemokines, cxc - metabolism |
5 |
|
chemoresistance |
5 |
|
cisplatin |
5 |
|
cytokines |
5 |
|
dna primers |
5 |
|
dna primers - chemistry |
5 |
|
dna probes |
5 |
|
dna-binding proteins - metabolism |
5 |
|
dna-binding proteins - physiology |
5 |
|
down-regulation - drug effects |
5 |
|
endothelin-1 - genetics |
5 |
|
endothelin-1 - metabolism |
5 |
|
energy metabolism - drug effects - physiology |
5 |
|
enzyme activity |
5 |
|
enzyme-linked immunosorbent assay |
5 |
|
epidermal growth factor - metabolism |
5 |
|
epithelial-mesenchymal transition - physiology |
5 |
|
fibrosis - drug therapy - pathology |
5 |
|
focal adhesion kinase 2 - metabolism - physiology |
5 |
|
gene expression regulation |
5 |
|
glucagon - blood |
5 |
|
glutathione - chemistry |
5 |
|
graft survival - drug effects - genetics |
5 |
|
graft survival - drug effects - immunology - physiology |
5 |
|
graft survival - physiology |
5 |
|
grp78 |
5 |
|
heme oxygenase (decyclizing) - biosynthesis |
5 |
|
heme oxygenase-1 |
5 |
|
hepatic steatosis |
5 |
|
hepatic stellate cell (hsc) |
5 |
|
hepatic stellate cells |
5 |
|
hepatocytes - cytology |
5 |
|
hsp70 heat-shock proteins - metabolism |
5 |
|
hypertension, portal - etiology - prevention & control |
5 |
|
hypoglycemic agents - pharmacology |
5 |
|
hypoxia |
5 |
|
immediate-early proteins - metabolism |
5 |
|
immunosuppressive agents - administration and dosage |
5 |
|
in situ nick-end labeling |
5 |
|
inflammasomes |
5 |
|
inflammatory response |
5 |
|
insulin - chemistry - pharmacology |
5 |
|
insulin receptor substrate proteins |
5 |
|
intercellular signaling peptides and proteins - metabolism |
5 |
|
interleukin-10 - biosynthesis |
5 |
|
intracellular signaling peptides and proteins |
5 |
|
kc |
5 |
|
liver - anatomy & histology |
5 |
|
liver - anatomy & histology - drug effects - ultrastructure |
5 |
|
liver - drug effects - injuries - metabolism |
5 |
|
liver cell carcinoma |
5 |
|
liver cirrhosis |
5 |
|
liver cirrhosis, experimental - surgery |
5 |
|
liver neoplasms - enzymology - pathology |
5 |
|
liver neoplasms - enzymology - pathology - ultrastructure |
5 |
|
liver neoplasms - pathology - surgery |
5 |
|
liver transplantation - adverse effects |
5 |
|
liver transplantation - immunology |
5 |
|
liver transplantation - pathology - physiology |
5 |
|
liver transplantation - physiology |
5 |
|
male |
5 |
|
map kinase signaling system |
5 |
|
map kinase signaling system - drug effects - physiology |
5 |
|
mapk |
5 |
|
matrix metalloproteinase-12 |
5 |
|
microscopy, electron |
5 |
|
models, animal |
5 |
|
multidrug resistance protein 1 |
5 |
|
neutrophil |
5 |
|
nitric oxide synthase - metabolism |
5 |
|
nitric oxide synthase type ii |
5 |
|
organ preservation |
5 |
|
organ preservation solutions - chemistry |
5 |
|
organ size |
5 |
|
oxygenation |
5 |
|
oxylab po2 |
5 |
|
p38 mitogen-activated protein kinases - metabolism |
5 |
|
phosphoproteins - physiology |
5 |
|
post-lt surveillance |
5 |
|
protein-serine-threonine kinases - physiology |
5 |
|
protein-tyrosine kinases - physiology |
5 |
|
proteins - metabolism |
5 |
|
proto-oncogene proteins - physiology |
5 |
|
raf kinases - metabolism |
5 |
|
raffinose - chemistry |
5 |
|
rap1 |
5 |
|
rats |
5 |
|
rats, inbred lew |
5 |
|
rats, sprague-dawley |
5 |
|
reperfusion injury - drug therapy |
5 |
|
reperfusion injury - metabolism - physiopathology |
5 |
|
reverse transcriptase polymerase chain reaction |
5 |
|
signal transduction - drug effects - physiology |
5 |
|
sirolimus - administration and dosage |
5 |
|
small-for-size graft |
5 |
|
somatostatin - therapeutic use |
5 |
|
stem cell |
5 |
|
sterol regulatory element binding protein 1 |
5 |
|
stress, mechanical |
5 |
|
surgery medical sciences |
5 |
|
time factors |
5 |
|
transcription factors - metabolism |
5 |
|
transcription factors - physiology |
5 |
|
transplantation, homologous |
5 |
|
transplantation, isogeneic |
5 |
|
tumor-initiating cell |
5 |
|
up-regulation |
5 |
|
up-regulation - physiology |
5 |
|
upr pathway |
5 |
|
adenosinergic signaling pathway |
4 |
|
aldose reductase |
4 |
|
apoa-1 |
4 |
|
biomaterial |
4 |
|
bregs |
4 |
|
caspase |
4 |
|
caspase 3 |
4 |
|
cell differentiation |
4 |
|
chemoembolization |
4 |
|
cytokine receptor gp130 - metabolism |
4 |
|
drug-induced liver injury - etiology - metabolism - pathology - surgery |
4 |
|
early allograft dysfunction |
4 |
|
early-phase |
4 |
|
entpd1/cd39 |
4 |
|
et5e/cd73 |
4 |
|
extracellular adenosine |
4 |
|
hcc recurrence |
4 |
|
hepatic ischemia reperfusion |
4 |
|
hepatic ischemia reperfusion injury |
4 |
|
hepatocytes - metabolism - pathology - transplantation |
4 |
|
hydroge |
4 |
|
inflammatory responses |
4 |
|
invasion |
4 |
|
ischemic injury |
4 |
|
laparoscopic liver resection |
4 |
|
liver regeneration |
4 |
|
liver steatosis |
4 |
|
lliver neoplasms |
4 |
|
macrophage activation |
4 |
|
mir-1246 |
4 |
|
momp |
4 |
|
neutrophils |
4 |
|
neutrophils migration |
4 |
|
nf-κb |
4 |
|
nf-κb signaling |
4 |
|
nuclear factor-κb |
4 |
|
open liver resection |
4 |
|
pi3-kinase/akt |
4 |
|
postoperative cytokines |
4 |
|
regulatory t cells |
4 |
|
t cell exhaustion |
4 |
|
alternative splicing events |
3 |
|
animal cell |
3 |
|
antineoplastic activity |
3 |
|
biomarker |
3 |
|
blood sampling |
3 |
|
cancer hallmarks |
3 |
|
carcinoma, hepatocellular - complications - drug therapy - metabolism |
3 |
|
cell count |
3 |
|
cell proliferation - drug effects |
3 |
|
circulating tumor cell |
3 |
|
cisplatin resistance |
3 |
|
clinical outcomes |
3 |
|
complement component |
3 |
|
cysteine - analogs and derivatives - pharmacology - therapeutic use |
3 |
|
diagnosis prediction |
3 |
|
epcs |
3 |
|
fibrosis |
3 |
|
garlic - chemistry |
3 |
|
hcc invasiveness |
3 |
|
hemoglobin-based oxygen carrier |
3 |
|
hepatic i/r injury |
3 |
|
hepatic ischemia/reperfusion |
3 |
|
immune response |
3 |
|
inflammasome |
3 |
|
intravital imaging |
3 |
|
ip10 |
3 |
|
lactate |
3 |
|
lipid metabolism |
3 |
|
liver neoplasms - complications - drug therapy - metabolism |
3 |
|
liver transplantation using steatotic graft |
3 |
|
living-related liver donors |
3 |
|
mdsc |
3 |
|
metabolism and immune cells |
3 |
|
oncology |
3 |
|
rapamycin |
3 |
|
response marker |
3 |
|
steatotic liver graft |
3 |
|
therapeutic potential |
3 |
|
therapeutic target |
3 |
|
transmembrane protein 47 |
3 |
|
tregs |
3 |
|
tumor growth |
3 |
|
tumor metastasis |
3 |
|
tumor-suppressive protein |
3 |
|
tumour recurrence |
3 |
|
yb1 |
3 |
|
yq23 |
3 |
|
liver -- cancer -- diagnosis. |
2 |
|
liver -- cancer -- prognosis. |
2 |
|
liver -- cancer -- treatment. |
2 |
|
acute cellular rejection |
1 |
|
adulthood |
1 |
|
developmental mycology |
1 |
|
edible mushrooms |
1 |
|
fruiting bodies, fungal - genetics - growth and development - metabolism |
1 |
|
gene expression regulation, developmental |
1 |
|
hepatocellular-carcinoma |
1 |
|
hydrophobins |
1 |
|
ketamine |
1 |
|
long-term potentiation |
1 |
|
neonatal exposure |
1 |
|
oligonucleotide array sequence analysis |
1 |
|
sage |
1 |
|
shiitake |
1 |
|
shiitake mushrooms - genetics - growth and development - metabolism |
1 |
